Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2009

01-12-2009 | Case Report

Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine

Authors: Dominique Levêque, Raoul Santucci, Julien Pavillet, Raoul Herbrecht, Jean Pierre Bergerat

Published in: International Journal of Clinical Pharmacy | Issue 6/2009

Login to get access

Abstract

Case description A French Caucasian man aged 39 with HIV infection was treated with abacavir/lamivudine and ritonavir/lopinavir. The patient (normal renal and liver functions) was diagnosed with a Burkitt lymphoma for which he was treated with cyclophosphamide day 1 to 5; doxorubicin day 1; methotrexate day 10; and vincristine day 1 and 8. At day 12, he suffered from abdominal pain associated with constipation. Paralytic ileus was diagnosed by study imaging. Ileus lasted 10 days necessitating parenteral feeding. Later on, a further cycle of chemotherapy with etoposide replacing vincristine was given and was well tolerated. Conclusion We speculate that an interaction between ritonavir/lopinavir and vincristine was responsible for this severe toxicity. Vincristine is transported by P-gp and is metabolized via CYP3A5. Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor. Lopinavir is also a P-gp inhibitor. Ritonavir and lopinavir might have delayed vincristine elimination. Clinicians should be aware of this possible interaction.
Literature
1.
go back to reference Levêque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J Clin Pharmacol. 2007;47:579–88.CrossRefPubMed Levêque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J Clin Pharmacol. 2007;47:579–88.CrossRefPubMed
2.
go back to reference Toghill PJ, Burke JD. Death from paralytic ileus following vincristine therapy. Postgrad Med J. 1970;46:330–1.CrossRefPubMed Toghill PJ, Burke JD. Death from paralytic ileus following vincristine therapy. Postgrad Med J. 1970;46:330–1.CrossRefPubMed
3.
go back to reference Bermudez M, Fuster JL, Llinares E, Galera A, Gonzales C. Itraconazole-related increased vincristine neurotoxicity. J Pediatr Hematol Oncol. 2005;27:389–92.CrossRefPubMed Bermudez M, Fuster JL, Llinares E, Galera A, Gonzales C. Itraconazole-related increased vincristine neurotoxicity. J Pediatr Hematol Oncol. 2005;27:389–92.CrossRefPubMed
4.
go back to reference Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract. 2009;15:175–82.CrossRef Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract. 2009;15:175–82.CrossRef
5.
go back to reference Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317–27.CrossRefPubMed Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317–27.CrossRefPubMed
6.
go back to reference Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther. 2008;327:248–57.CrossRefPubMed Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther. 2008;327:248–57.CrossRefPubMed
7.
go back to reference Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica. 2006;36:1191–200.CrossRefPubMed Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica. 2006;36:1191–200.CrossRefPubMed
8.
go back to reference Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312:83–91. Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312:83–91.
9.
go back to reference Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573–81.CrossRefPubMed Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573–81.CrossRefPubMed
10.
go back to reference Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non Hodgkin lymphoma. Cancer. 2001;91:155–63.CrossRefPubMed Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non Hodgkin lymphoma. Cancer. 2001;91:155–63.CrossRefPubMed
Metadata
Title
Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine
Authors
Dominique Levêque
Raoul Santucci
Julien Pavillet
Raoul Herbrecht
Jean Pierre Bergerat
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2009
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9323-y

Other articles of this Issue 6/2009

International Journal of Clinical Pharmacy 6/2009 Go to the issue